Arcellx, Inc. (ACLX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $115.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10. Specifically: Elevated put/call ratio: 8.31; Below-average business quality; Rich valuation.
Arcellx is a clinical-stage biotechnology company developing CAR-T immunotherapies for cancer and other incurable diseases, with lead program anito-cel (CART-ddBCMA) for multiple myeloma. A BLA was submitted to the FDA in December 2025 with a PDUFA action date of December 23,... Read more
Sell if holding. Engine safety override at $115.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10. Specifically: Elevated put/call ratio: 8.31; Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 3.9/10, high confidence.
Passes 4/6 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHSupplierKite10-K Item 1A: 'We depend on Kite for certain development, manufacturing and commercialization activities with respect to certain of our product candidates'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
4 floor-breakers
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Priced at a premium — multiples above sector norms. Needs delivery on growth + margins to justify.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $115.11: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 3.9/10. Specifically: Elevated put/call ratio: 8.31; Below-average business quality; Rich valuation. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $114.87. Score 3.9/10, high confidence.
Take-profit target: $112.83 (-1.9% upside). Prior stop was $114.87. Stop-loss: $114.87.
Concentration risk — Supplier: Kite; Target reached (-15.2% upside); Quality below floor (2.1 < 4.0).
Arcellx, Inc. trades at a P/E of N/A (forward -66.4). TrendMatrix value score: 3.0/10. Verdict: Sell.
23 analysts cover ACLX with a consensus score of 2.8/5. Average price target: $112.
What does Arcellx, Inc. do?Arcellx is a clinical-stage biotechnology company developing CAR-T immunotherapies for cancer and other incurable...
Arcellx is a clinical-stage biotechnology company developing CAR-T immunotherapies for cancer and other incurable diseases, with lead program anito-cel (CART-ddBCMA) for multiple myeloma. A BLA was submitted to the FDA in December 2025 with a PDUFA action date of December 23, 2026. Arcellx entered into a merger agreement with Gilead in February 2026; the company has incurred a net loss of approximately $2.3 billion since inception.